Tech Company Financing Transactions
Surrozen Funding Round
The Column Group and private investors invested in a $33 million Series A funding round for Surrozen. The round was announced by the company on 2/16/2017.
Transaction Overview
Company Name
Announced On
2/16/2017
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series A
Investors
The Column Group (Lead Investor) (David Goeddel)
Proceeds Purpose
The funds will be used to implement a broad-based drug discovery platform aimed at unlocking the therapeutic potential of Wnt signaling, which plays a central role in organism development, stem-cell maintenance and tissue regeneration.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
171 Oyster Point Blvd. 400
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Surrozen Inc. is a biopharmaceutical company focused on harnessing the Wnt pathway for applications in regenerative medicine. Founded on breakthrough science from Stanford University and backed by The Column Group, Surrozen is implementing a surrogate Wnt platform with the potential to unlock stem cell control in a wide array of human tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Timothy Kutzkey
Chief Executive Officer
Craig Parker
Chief Medical Officer
Trudy Vanhove
Chief Scientific Officer
Wen-Chen Yeh
Vice President
Yang Li
VP - Bus. Development
Reza Afkhami
VP - General Counsel
Sheela Peterson
VP - Human Resources
Christine McKinley
Browse more venture capital transactions:
Prev: 2/16/2017: miDrive venture capital transaction
Next: 2/16/2017: SwipeRX venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs